... and we may fall terminally behind in the race to market, unless apabetalone is significantly better. But 75-100% significant improvement in 3-5 days is incredible and hard to beat, especially if second to the market. Although there would "probably" be room for two in that market. Perhaps our longer term safety profile, and other potential cardio/renal/PAH/Etc benefits would help?

Would be better to be first in the Covid market though, with demand through the roof. Ugh